Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-09-11 DOI:10.3324/haematol.2025.288004

Koji Kawamura,Junya Kanda,Sachiko Seo,Fumihiko Kimura,Masahiro Hirayama,Naoyuki Uchida,Noriko Doki,Wataru Takeda,Tetsuya Nishida,Yuta Katayama,Masatsugu Tanaka,Masashi Sawa,Satoshi Yoshihara,Tetsuya Eto,Toshiro Kawakita,Hirohisa Nakamae,Shuichi Ota,Fumihiko Ishimaru,Takahiro Fukuda,Yoshiko Atsuta,Yoshinobu Kanda

引用次数: 0

Abstract

Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and older patients. We compared the transplant outcomes among human leukocyte antigen (HLA)-matched related donors (M-RDs, n=4,106), HLA 1-antigen-mismatched related donors (1MM-RDs, n=592), HLA 2-3-antigen-mismatched related donors (23MM-RDs, n=882), HLA-matched unrelated donors (M-UDs, n=3,927), HLA 1-locus-mismatched unrelated donors (1MM-UDs, n=2,474), and unrelated cord blood units (U-CBs, n=5,867) between patients aged.

查看原文本刊更多论文

同种异体造血移植供体选择优先顺序的年龄相关差异。

由于供体年龄、器官功能和对移植物抗宿主病的抵抗力不同，患者年龄可能会影响同种异体造血干细胞移植（allogeneic hematopoietic stem cell transplantation, allo-HCT）中供体选择的优先顺序。我们比较了人类白细胞抗原（HLA）匹配相关供者（m - rd, n=4,106）、HLA 1抗原错配相关供者（1mm - rd, n=592）、HLA 2-3抗原错配相关供者（23mm - rd, n=882）、HLA匹配非相关供者（m - ud, n=3,927）、HLA 1基因座错配非相关供者（1MM-UDs, n=2,474）和非相关脐带血供者（U-CBs, n=5,867）年龄患者的移植结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.